



**Sociedad Argentina de  
Terapia Radiante Oncológica**

**III Best of ASTRO**



SCIENCE OF TODAY  
HOPE FOR TOMORROW

**ARGENTINA**

**17 y 18 de Mayo de 2018**  
**Hotel Melia Buenos Aires, Reconquista 945**  
**Ciudad Autónoma de Buenos Aires**



SCIENCE OF TODAY  
HOPE FOR TOMORROW

**ARGENTINA**

**Este evento se realiza con licencia de American Society of Radiation Oncology  
“ASTRO” con el objetivo de difundir los trabajos con mejor puntuación del ASTRO  
Annual Meeting del año 2017, San Diego, California, USA**

**07:30 – 15:30 hs. Acreditación**

**08:30 – 09:55 hs. Módulo 1: Cabeza y Cuello**

**08:30 – 08:35 hs. Presidente:** Dra. Cecilia Coll, Instituto de Radioterapia Cuyo, Mendoza

**Coordinador:** Dr. Marcos David Pereira, Instituto Ángel Roffo, Bs. As.

**Disertantes:**

**08:35 – 08:45 hs. Dr. Diego Fernández, Centro Médico Dean Funes, Córdoba**

- |                                                                                                                                                                       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 1: (290)</b> A Phase II Dose and Volume De-escalation Trial for High- and Low-risk HPV+ Oropharynx Cancer: Efficacy, Toxicity and Dosimetric Analyses   |
| ▪ <b>Abstract 2: (263)</b> Comparison of Electronic Brachytherapy and Mohs Micrographic Surgery—A Matched Pair Cohort Study for Treatment of Non-melanoma Skin Cancer |

**08:45 – 08:55 hs. Dra. Patricia Bruno, Centro de Oncología y RT, Villa María, Córdoba**

- |                                                                                                                                                                                                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 3: (92)</b> Quantification of HPV-16 in Circulating Tumor DNA During De-intensified Chemoradiation Therapy for Favorable-risk HPV-associated Oropharyngeal Squamous Cell Carcinoma |
| ▪ <b>Abstract 4: (293)</b> Nodal Radiographic Prognostic Factors in the New Stage I p16-Positive Oropharyngeal Cancer of the AJCC 8th Edition: Is All N1 Disease the Same?                       |

**08:55 – 09:05 hs. Dra. Carmen Castro, Hospital Alemán, Buenos Aires**

- |                                                                                                                                                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 5: (292)</b> A Personalized Approach Using Hypoxia Resolution to Guide Curative-intent Radiation Therapy Dose-reduction to 30 Gy: A Novel De-escalation Paradigm for HPV-associated Oropharynx Cancers Treated with Concurrent Chemoradiation Therapy |
| ▪ <b>Abstract 6: (259)</b> Eating as Treatment: A Stepped Wedge Randomized Controlled Trial to Improve Nutrition in Head and Neck Cancer Patients Undergoing Radiation Therapy                                                                                      |

**09:05 – 09:15 hs. Dr. Luis Linares, Director Médico de HOPE International, Guatemala**

- |                                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 7: (97)</b> Development of Laryngeal Cancer Nomograms from Pooled Data of Two Trials of Concurrent Chemoradiation: NRG Oncology RTOG 0129 and RTOG 0522              |
| ▪ <b>Abstract 8: (261)</b> The Impact of Total Laryngectomy on Non-oncologic Causes of Death in Patients Treated with Radiation Therapy for Advanced Larynx and Hypopharynx Cancer |

**09:15 – 09:55 hs. Mesa de Discusión:** **Coordinador:** Dr. Marcos David Pereira

**Panelistas:**

Dra. Cecilia Coll (RT), Dr. Diego Fernández (RT),  
Dra. Patricia Bruno (RT), Dra. Carmen Castro (RT), Dr. Luis Linares (RT)  
Dr. Pedro Saco, Cirugía Oncológica, Hospital Austral, Buenos Aires  
Dr. Raúl Giglio, Oncología Clínica, Instituto Ángel Roffo, Buenos Aires

**09:55 – 10:25 hs. Inauguración Best of ASTRO**

**Dra. Luisa Rafailovici, Directora Best of ASTRO**

**Prof. Dr. Miguel Galmés, Presidente Asociación Médica Argentina**

**Instituto Nacional del Cáncer**

**María Graziella Donnet De Acosta Güemes, Presidente de LALCEC**

**Dra. Higinia Cardenes, en nombre de los invitados extranjeros**

**10:25 – 10:55 hs. Intervalo Café**

**10:55 – 11:45 hs. Sesión Educativa**

***Strategies to Combine Immune Checkpoint Inhibitors and Radiation***

**10:55 – 11:00 hs. Presidente:** Dr. Miguel Torres, Centro C.O.R., Montevideo, Uruguay

**11:00 – 11:30 hs. Disertante:** Dr. Gustavo Ferraris, Centro Médico Dean Funes, Córdoba

**11:30 – 11:45 hs. Preguntas del público**

**11:45 – 13:15 hs. Módulo 02: Genitourinario**

**11:45 – 11:50 hs. Presidente:** Dr. Jorge Chiozza, Vidt Centro Médico, Buenos Aires

**Coordinadora:** Dra. Carolina Chacón, Instituto Alexander Fleming, Bs As

**Disertantes:**

**11:50 – 12:00 hs. Dra. Daniela Bejarano, Vidt Centro Médico, Buenos Aires**

- **Abstract 1: (210)** Development and Validation of a Novel Clinical-Genomic Risk Group Classification for Prostate Cancer Incorporating Genomic and Clinicopathologic Risk
- **Abstract 2: (1082)** Low-Dose-Rate Brachytherapy for Prostate Cancer: Outcomes Beyond 10-years of Follow-Up

**12:00 – 12:10 hs. Dra. Nimbe Barroso, Universidad Autónoma de Guadalajara, México**

- **Abstract 3: (1)** A Prospective Phase II Trial of Transperineal Ultrasound-guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiation Therapy (NRG/RTOG 0526): Initial Report of Late Toxicity Outcome
- **Abstract 4: (336)** 5-Year Outcomes of a Phase I Dose Escalation Study Using Stereotactic Body Radiosurgery for Patients With Clinically Localized Prostate Cancer

**12:10 – 12:20 hs. Dr. Luis Linares, Director Médico de HOPE International, Guatemala**

- **Abstract 5: (282)** Extremely Dose-escalated Radiation Therapy Improves Cancer-Specific Survival Compared With Radical Prostatectomy or Conventionally Dose-escalated Radiation Therapy in Gleason Score 9-10 Prostate Adenocarcinoma: A Multi-institutional Analysis of 1,403 Patients
- **Abstract 6: (209)** Multi-institutional Outcomes of Postprostatectomy Adjuvant Versus Early Salvage Radiation Therapy in Prostate Cancer Patients With Adverse Pathologic Features

**12:20 – 12:30 hs. Dr. Pedro Kasdorf, Inst. Nacional del Cáncer, Montevideo, Uruguay**

- **Abstract 7: (LBA-9)** 68Ga-PSMA PET/CT Mapping of Early Biochemical Recurrence (PSA <1 ng/mL) after Primary Surgery in 270 Patients: Impact on Salvage Radiotherapy Planning
- **Abstract 8: (1089)** The Use of Chemotherapy Instead of Radiation Therapy Does Not Reduce the Incidence of Second Cancers in Survivors of Early Stage Seminoma: A Population-based Study from British Columbia

**12:30 – 12:35 hs. Dr. Javier Otero, Hospital Austral, Buenos Aires**

- **Abstract 9: (330)** Individual Patient Data Meta-analysis of SBRT Kidney: A Report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)

**12:35 – 13:15 hs. Mesa de Discusión:** Coordinadora: Dra. Carolina Chacon

**Panelistas:**

Dr. Jorge Chiozza (RT), Dra. Daniela Bejarano (RT), Dra. Nimbe Barroso (RT),  
Dr. Luis Linares (RT), Dr. Pedro Kasdorf (RT), Dr. Javier Otero (RT),  
Dr. Marcelo Blanco Villalba, Oncología Clínica, Centro Médico Austral  
Dr. Carlos Scorticati, Urología, Hospital de Clínicas, Buenos Aires  
Dr. Luis Montes de Oca, Urología, CDU, Buenos Aires

**13:15 – 14:00 hs. Simposio DeLeC (Lunch Box)**

**14:00 – 14:45 hs. Almuerzo Libre**

*Organizado por el Capítulo de Jóvenes Radioterapeutas de SATRO*

**14:45 – 16:10 hs. Módulo 3: Cuidados Paliativos**

**14:45 – 14:50 hs. Presidente:** Dr. Ignacio Abregú, Centro de Radioterapia, San Juan

**Coordinadores:** Dr. José Máximo Barros,  
Centro de Radioterapia Hospital Austral, Bs. As.  
Dr. Federico Díaz, Instituto Mevaterapia, Buenos Aires

**Disertantes:**

**14:50 – 15:00 hs. Dr. Luis Carvajal, Terapia Radiante, La Plata, Pcia Bs As**

- |                                                                                                       |
|-------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 1: (182)</b> Palliative Radiation for Bone Metastases: Reconsidering the Optimal Timing |
| ▪ <b>Abstract 2: (183)</b> The NEAT Predictive Model for Survival in Patients with Advanced Cancer    |

**15:00 – 15:10 hs. Dra. María Angélica Molina, Instituto Ángel Roffo, Buenos Aires**

- |                                                                                                                                                                         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 3: (184)</b> Radiotherapy for Lung Cancer in the Intensive Care Unit: A Population-based Analysis                                                         |
| ▪ <b>Abstract 4: (185)</b> Assessing the Utility of a Prognostication Model to Predict One-year Mortality in Patients Receiving Radiation Therapy for Spinal Metastases |

**15:10 – 15:20 hs. Dra. María José Girola, Vidt Centro Médico, Bs. As.**

- |                                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 5: (186)</b> Palliative Radiation Therapy for Pediatric Patients: Parental Perceptions                                                                               |
| ▪ <b>Abstract 6: (187)</b> The ADscopal Effect? Control of Partially Irradiated Versus Completely Irradiated Tumors on a Prospective Trial of Pembrolizumab and SBRT Per NRG-BR001 |

**15:20 – 15:30 hs. Dra. Beatriz Mazza, Instituto Ángel Roffo, Buenos Aires**

- |                                                                                                  |
|--------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 7: (188)</b> Palliative Radiation Oncology: A New Direction in Care                |
| ▪ <b>Abstract 8 (189)</b> Informal Caregiver Quality of Life in a Palliative Oncology Population |

**15:30 – 16:10 hs. Mesa de Discusión**

**Coordinadores:** Dr. José Máximo Barros (RT), Dr. Federico Díaz (RT)

**Panelistas:**

Dr. Ignacio Abregú (RT), Dr. Luis Carvajal (RT), Dra. Beatriz Mazza (RT)  
Dra. María Angélica Molina (RT), Dra. María José Girola (RT)  
Dra. Mariana Pérez de Antueno, Hospital Austral, Buenos Aires  
Dr. Tomás Lagos, Med. Interna, Cuidados Paliativos, Hosp. Univ. Austral

**16:10 – 17:35 hs. Módulo 4: Gastrointestinal**

**16:10 – 16:15 hs. Presidente:** Dra. Nimbe Barroso  
Universidad Autónoma de Guadalajara, México

**Coordinadora:**

Dra. Higinia Cardenes, Weill Cornell University, New York, USA

**Disertantes:**

**16:15 – 16:25 hs. Dr. Jorge Sar, Centro de Radioterapia, Rio Cuarto, Córdoba**

- |                                                                                                                                                                                                                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"><li>▪ <b>Abstract 1: (306)</b> Enteral Nutrition Improves Nutritional Status, Treatment Tolerance and Outcomes in Patients with Esophageal Cancer Undergoing Concurrent Chemoradiation Therapy: Results of a Prospective, Randomized, Controlled, Multicenter Trial (NCT 02399306)</li></ul> |
| <ul style="list-style-type: none"><li>▪ <b>Abstract 2: (307)</b> Phase II Study of Adjuvant Chemoradiation Therapy Using Docetaxel/ Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiation Therapy with Concurrent Docetaxel in Patients with Completely (R0) Resected Gastric Carcinoma</li></ul>            |

**16:25 – 16:35 hs. Dr. Gastón Lemoine, Instituto de Radiaciones, Salta**

- |                                                                                                                                                                                                                 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"><li>▪ <b>Abstract 3: (308)</b> Dose Escalation in Locally Advanced Pancreatic Cancer Patients Receiving Chemoradiation Therapy</li></ul>                                      |
| <ul style="list-style-type: none"><li>▪ <b>Abstract 4: (191)</b> Neutrophils Predicting Tumor Local Control After Chemoradiation Therapy in Locally Advanced Pancreatic Carcinoma in the LAP 07 Trial</li></ul> |

**16:35 – 16:45 hs. A Confirmar**

- |                                                                                                                                                                                                                                         |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"><li>▪ <b>Abstract 5: (192)</b> The Clinical Implications of Soluble PD-L1 in Hepatocellular Carcinoma Patients Treated with Radiation Therapy</li></ul>                                               |
| <ul style="list-style-type: none"><li>▪ <b>Abstract 6: (311)</b> Improved Local Control with Stereotactic Body Radiation Therapy Compared to Radiofrequency Ablation in the Treatment of Unresectable Intrahepatic Metastases</li></ul> |

**16:45 – 16:55 hs. Dra. Claudia Benavento, Hospital B. Rivadavia, Buenos Aires**

- |                                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"><li>▪ <b>Abstract 7: (144)</b> Non-operative Management for Locally Advanced Rectal Cancer in the Veterans Health Administration</li></ul>                                                     |
| <ul style="list-style-type: none"><li>▪ <b>Abstract 8: (138)</b> NRG Oncology/RTOG 0529: Long-term Outcomes of Dose-painted Intensity Modulated Radiation Therapy, 5-Fluorouracil and Mitomycin-C in Anal Canal Cancer</li></ul> |

**16:55 – 17:35 hs. Mesa de Discusión: Coordinadora:** Dr. Higinia Cardenes

**Panelistas:**

Dra. Nimbe Barroso (RT), Dr. Jorge Sar (RT), Dr. Gastón Lemoine (RT),  
Dra. Claudia Benavento (RT)  
Dr. Mario Barugel, Oncología, Hosp. Gastroenterología Udaondo, Bs. As.  
Dr. Enrique Roca, Oncología, Hosp. Gastroenterología Udaondo, Bs. As.

**17:35 – 18:05 hs. Intervalo Café**

**18:05 – 19:35 hs. Módulo 5: Hematología Oncológica**

**18:05 – 18:10 hs. Presidente:** Dr. Ricardo Alva, Hospital Naval, Buenos Aires

**Coordinador:**

Dr. Mario Di Nucci,  
Centro de Oncología y Radioterapia, Mar del Plata, Pcia. Bs. As.

**Disertantes:**

**18:10 – 18:20 hs. Dr. Juan José Galarraga,**  
**Centro de Oncología y RT, Mar del Plata, Pcia. Bs. As.**

- |                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 1: (298)</b> Phase II Study of Dose-reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma |
| ▪ <b>Abstract 2: (131)</b> Rainbows and Butterflies: Individualized IMRT Planning for Mediastinal Lymphoma                               |

**18:20 – 18:30 hs. Dr. Hernán Castro Vita, Centro Méd. Dean Funes, Córdoba**

- |                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 3: (132)</b> Non-coplanar Butterfly VMAT and Deep Inspiration Breath Hold for Mediastinal Lymphoma: Do We Need Both?                                   |
| ▪ <b>Abstract 4: (136)</b> Potential to Reduce Toxicity: Clinical and Dosimetric Predictors of Hypothyroidism After Radiation Therapy With IMRT for Hodgkin Lymphoma |

**18:30 – 18:40 hs. Dr. Óscar Gómez Orrego, Centro de Radioterapia San Martín, Bs. As.**

- |                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 5: (299)</b> Cardiac Disease and Lifestyle Risk Factors Following Hodgkin Lymphoma: An EORTC Lymphoma Group and GELA Follow-up Study |
| ▪ <b>Abstract 6: (302)</b> Role of Adjuvant Radiotherapy for Early-stage Anaplastic Large Cell Lymphoma: Analysis of the National Cancer Database  |

**18:40 – 18:50 hs. Dr. Miguel Castiglioni, Instituto de Tumores Rosario, Santa Fe**

- |                                                                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 7: (303)</b> Impact of Consolidation Radiation Therapy in Stage III-IV Hodgkin Lymphoma After Complete Metabolic Response by Gallium or PET-CT                                  |
| ▪ <b>Abstract 8: (137)</b> Augmented Total Body Irradiation With a Cranial Boost Before Stem Cell Transplantation Protects Against Posttransplant CNS Relapse in Acute Lymphoblastic Leukemia |

**18:50 – 18:55 hs. Dra. Soledad Colombo, Instituto Mevaterapia, Buenos Aires**

- |                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 9: (135)</b> Importance of PET-CT Radiomics Features in Outcomes Prognostication for Mediastinal Hodgkin Lymphoma |
|---------------------------------------------------------------------------------------------------------------------------------|

**18:55 – 19:35 hs. Mesa de Discusión: Coordinador:** Dr. Mario Di Nucci

Dr. Ricardo Alva (RT), Dr. Juan José Galarraga (RT),  
Dr. Hernán Castro Vita (RT), Dr. Óscar Gómez Orrego (RT),  
Dr. Miguel Castiglioni (RT), Dra. Soledad Colombo (RT)  
Dra. Astrid Pavlovsky, Onco-Hematología,  
Centro de Hematología Pavlovsky, Buenos Aires



**08:30 – 12:30 hs. Acreditación**

**09:00 – 10:30 hs. Módulo 6: Mama**

**09:00 – 09:05 hs. Presidente:** Dra. Verónica Vázquez Balcarce, Vidt Centro Médico, B. A.

**Coordinador:** Dr. Hugo Marsiglia, Instituto Oncológico FALP, Chile

**Disertantes:**

**09:05 – 09:15 hs. Dra. Luisa Rafailovici, Vidt Centro Médico, Buenos Aires**

- **Abstract 1: (5)** Hypofractionated Radiation Therapy After Mastectomy for the Treatment of High-risk Breast Cancer: Five-year Follow-up Result of a Randomized Trial
- **Abstract 2: (116)** Oncotype Score as a Predictor of Local-regional Recurrence in Early Stage Breast Cancer (BC)

**09:15 – 09:25 hs. Dra. Adela Poitevin, Unidad de Radioterapia de Médica Sur, México**

- **Abstract 3: (10)** Lymphedema Risk Following Regional Nodal Irradiation in Breast Cancer: Implications for Field Arrangement and Treatment Volume
- **Abstract 4: (120)** Local-regional Recurrence in Women with N0/N1mi, HER2-Positive Breast Cancer: Results from a Prospective Multi-institutional Study (The APT Trial)

**09:25 – 09:30 hs. Dra. Verónica Vázquez Balcarce, Vidt Centro Médico, Bs As**

- **Abstract 5: (9)** Postmastectomy Radiation Therapy for Node-negative Breast Cancer with Tumor Size of Five Centimeter or More: A Meta-analysis

**09:30 – 09:40 hs. Dra. María Fernanda Díaz Vázquez, Centro Médico Dean Funes, Córdoba**

- **Abstract 6: (8)** Single Stage Permanent Implant Reconstruction Has Better Outcome Than Tissue Expander/Implant in Patients Treated with Postmastectomy Radiation
- **Abstract 7: (113)** Oncotype Score and Benefit of Post-mastectomy Radiotherapy in T1-2 N1 Breast Cancer.

**09:40 – 09:50 hs. Dr. Luis Reñe, Centro de Radioterapia, Rosario, Provincia de Sta. Fe**

- **Abstract 8: (7)** Evaluating Radiation Omission Decisions in a Population-based Sample of Older Adults Receiving Lumpectomy for Breast Cancer
- **Abstract 9: (13)** Hypofractionated Whole Breast Irradiation in Women Less Than 50 Years Old Treated on Prospective Protocols: A Report on Long-term Cosmesis

**09:50 – 10:30 hs. Mesa de Discusión: Coordinador:** Dr. Hugo Marsiglia

**Panelistas:**

Dra. Verónica Vázquez Balcarce (RT), Dra. Luisa Rafailovici (RT),  
Dra. Adela Poitevin (RT), Dra. María Fernanda Díaz Vázquez (RT),  
Dr. Luis Reñe (RT)

Dr. Federico Coló, Patología Mamaria, Instituto Alexander Fleming, Bs As  
Dr. Gonzalo Recondo, Oncología, CEMIC, Buenos Aires

**10:30 – 11:00 hs. Intervalo Café**

**11:00 – 11:40 hs. Módulo 7: Física / Biología**

**11:00 – 11:05 hs. Presidente:** Lic. Víctor Bourel, Universidad Favaloro, Buenos Aires

**Disertantes:**

**11:05 – 11:15 hs. Lic. Karla Torzsok, Instituto Oncológico FALP, Chile**

- |                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 1: (99)</b> Incident Learning for Stereotactic Radiation Therapy from RO-ILS: Radiation Oncology Incident Learning System® |
| ▪ <b>Abstract 2: (106)</b> Regional Dose Differences Associated with Radiation-induced Acute Severe Dysphagia                            |

**11:15 – 11:25 hs. Dra. Alba Güerci, Terapia Radiante, La Plata, Pcia. de Buenos Aires**

- |                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 3: (2)</b> Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome |
| ▪ <b>Abstract 4: (47)</b> Intrinsic Immune Landscapes Between Radiosensitive and Radioresistant Tumors                                |

**11:25 – 11:32 hs. Comentarios Finales** Lic. Víctor Bourel (Física)

**11:32 – 11:39 hs. Comentarios Finales** Dra. Catalina Pogany (Biología)  
Instituto Ángel Roffo, Buenos Aires

**11:40 – 13:05 hs. Módulo 8: Ginecológico**

**11:40 – 11:45 hs. Presidente:** Dr. Mauro Mattio, Vidt Centro Médico, Buenos Aires

**Coordinadora:**

Dra. Higinia Cardenes, Weill Cornell University, New York, USA

**Disertantes:**

**11:45 – 11:55 hs. Dr. Pablo Menéndez, Instituto Ángel Roffo, Bs. As.**

- |                                                                                                                                                                                                                                                                                                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"><li>▪ <b>Abstract 1: (LBA-1)</b> A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-risk, Early Stage Endometrial Cancer: A Gynecology Oncology Group Study</li></ul> |
| <ul style="list-style-type: none"><li>▪ <b>Abstract 2: (48)</b> Distinct Profile of Circulating Endothelial Progenitor Cells and Apoptotic Endothelial Cells During Chemoradiation as Individualized Biomarkers for Long-term Prognosis and Severe Toxicity in Cervical Cancer Patients</li></ul>          |

**11:55 – 12:05 hs. Dr. Álvaro Luongo Gardi, COR, Montevideo, Uruguay**

- |                                                                                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"><li>▪ <b>Abstract 3: (241)</b> Increased Diversity of the Intestinal Microbiome Predicts for Lower Rates of Patient Reported Acute Gastrointestinal Toxicity in Women Receiving Radiation Therapy for Cervical Cancer</li></ul> |
| <ul style="list-style-type: none"><li>▪ <b>Abstract 4: (239)</b> Adjuvant Chemoradiation Therapy for Clear Cell Carcinoma of the Ovary: A Population based Study of Pelvic Versus Whole Abdominal Radiation Therapy</li></ul>                                     |

**12:05 – 12:15 hs. Dra. Marcela de la Torre, Centro CDT, Buenos Aires**

- |                                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"><li>▪ <b>Abstract 5: (242)</b> Multi-institutional Analysis of Vaginal Brachytherapy Without External Beam Radiation Therapy for Stage II Endometrial Cancer Patients</li></ul> |
| <ul style="list-style-type: none"><li>▪ <b>Abstract 6: (1128)</b> Vaginal Brachytherapy Boost in Margin Positive Early Stage Cervical Cancer</li></ul>                                                            |

**12:15 – 12:25 hs. Dra. Adela Poitevin, Unidad de Radioterapia de Médica Sur, Mexico**

- |                                                                                                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"><li>▪ <b>Abstract 7: (55)</b> Outcomes and Patterns of Relapse Following Definitive Radiation Therapy for Treatment of Oligometastatic Cervical Cancer</li></ul>                  |
| <ul style="list-style-type: none"><li>▪ <b>Abstract 8: (1134)</b> Improved Disease Control with Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: A Pooled Multi-institutional Analysis</li></ul> |

**12:25 – 13:05 hs. Mesa de Discusión:** Coordinadora: Dra. Higinia Cardenes

**Panelistas:**

Dr. Mauro Mattio (RT), Dr. Pablo Menéndez (RT), Dra. Adela Poitevin (RT),  
Dr. Álvaro Luongo Gardi (RT), Dra. Marcela de la Torre (RT),  
Médico Oncólogo a confirmar

**13:05 – 13:50 hs. Simposio Varian Medical Systems**

**13:50 – 14:50 hs. Lunch – Invitación SATRO**

**14:50 – 16:15 hs. Módulo 9: Sistema Nervioso Central**

**14:50 – 14:55 hs. Presidente:** A confirmar

**Coordinadora:** Dra. Ana Mabel Martínez, Vidt Centro Médico, Bs As

**Disertantes:**

**14:55 – 15:05 hs. Dr. Eduardo Weltman, H. Israelita Albert Einstein, San Pablo, Brasil**

- |                                                                                                                                                                                                                                             |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 1: (215)</b> MGMT Promoter Methylation Status Independently Predicts Overall Survival in Anaplastic Astrocytoma in NRG Oncology/RTOG 9813: A Phase III Trial of Radiation Plus Nitrosourea Versus Radiation Plus Temozolomide |
| ▪ <b>Abstract 2: (217)</b> Does the Addition of Valproic Acid to Concurrent Radiation Therapy and Temozolomide Improve Patient Outcome? Correlative Analysis of RTOG 0525, SEER and a Phase II NCI Trial                                    |

**15:05 – 15:15 hs. Dr. Lucas Causa, Centro Médico Dean Funes, Córdoba**

- |                                                                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 3: (342)</b> The Risk of Radiation Necrosis Following Stereotactic Radiosurgery with Concurrent Systemic Therapies                                                                          |
| ▪ <b>Abstract 4: (339)</b> Imaging-based Outcomes for 24 Gy in 2 Daily Fractions for Patients with De Novo Spinal Metastases Treated with Spine Stereotactic Body Radiation Therapy: An Emerging Standard |

**15:15 – 15:25 hs. Dr. Carlos Donoso, Vidt Centro Médico, Buenos Aires**

- |                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 5: (1006)</b> Implications of HER2 Status on Local Control and Adverse Radiation Effects After Stereotactic Radiosurgery for Brain Metastases of Breast Cancer                                                                                 |
| ▪ <b>Abstract 6: (337)</b> Phase I Study of Spinal Cord Constraint Relaxation with Single Session Spine Stereotactic Radiosurgery in the Primary Management of Patients with Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression |

**15:25 – 15:35 hs. Dr. Marcelo Andrade Irusta, Vidt Centro Médico, Buenos Aires**

- |                                                                                                           |
|-----------------------------------------------------------------------------------------------------------|
| ▪ <b>Abstract 7: (214.5)</b> High-risk Meningioma: Initial Outcomes from NRG Oncology/RTOG 0539           |
| ▪ <b>Abstract 8: (1007)</b> Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease |

**15:35 – 16:15 hs. Mesa de Discusión:** **Coordinadora:** Dra. Ana Mabel Martínez

**Panelistas:**

Dra. Claudia Ceranto (RT), Dr. Eduardo Weltman (RT),

Dr. Lucas Causa (RT), Dr. Carlos Donoso (RT),

Dr. Marcelo Andrade (RT)

Dra. Alejandra Rabadán, Neurocirugía, Inst. Alfredo Lanari, UBA, Bs. As.

Dr. Alejandro Muggeri, Oncología Clínica, Instituto FLENI, Buenos Aires

**16:15 – 16:45 hs. Intervalo Café**

**16:45 – 18:15 hs. Módulo 10: Pulmón**

**16:45 – 16:50 hs. Presidente:** A confirmar

**Coordinadora:** Dra. Berta Roth, Instituto Ángel Roffo, Buenos Aires

**Disertantes:**

**16:50 – 17:00 hs. Dr. Carlos Cardiello, Hospital Militar, Buenos Aires**

▪ **Abstract 1: (33)** Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients with Stage I Peripheral Non-small Cell Lung Cancer

▪ **Abstract 2: (35)** SBRT for Central Tumors in Early Stage NSCLC Patients

**17:00 – 17:10 hs. Dr. Pablo Castro Peña, Instituto de Radioterapia, Fundación Marie Curie, Córdoba**

▪ **Abstract 3: (224)** The International Atomic Energy Agency Randomized Trial on Chemotherapy With or Without Radiation Therapy in Advanced Non-small Cell Lung Cancer (NCT00864331)

▪ **Abstract 4: (223)** Quality of Life Outcomes in a Phase III Randomized Trial of Optimization of Treatment of Advanced Non-small Cell Lung Cancer Using Radiation Therapy and Chemotherapy: IAEA Multicentric Randomized Phase 3 Study (NCT00864331)

**17:10 – 17:20 hs. Dra. María Luisa Filomia, Vidt Centro Médico, Buenos Aires**

▪ **Abstract 5: (227)** Long-term Results of RTOG 0617: A Randomized Phase III Comparison of Standard Dose Versus High Dose Conformal Chemoradiation Therapy +/- Cetuximab for Stage III NSCLC

▪ **Abstract 6: (LBA-3)** Consolidative Radiotherapy for Limited Metastatic Non-small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

**17:20 – 17:30 hs. Dr. Carlos Pizzo, Terapia Radiante Cumbres, Rosario, Santa Fe**

▪ **Abstract 7: (LBA-4)** PACIFIC: A Double-blind, Placebo-controlled Phase III Study of Durvalumab as Consolidation Therapy after Chemoradiation in Patients with Locally Advanced, Unresectable NSCLC

▪ **Abstract 8: (323)** Incidence of Pneumonitis in Metastatic Lung Cancer Patients Receiving Immune Checkpoint Inhibitors With or Without Thoracic Radiation Therapy

**17:30 – 17:35 hs. A Confirmar**

▪ **Abstract 9: (LBA-5)** Phase II 5-arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies

**17:35 – 18:15 hs. Mesa de Discusión: Coordinadora:** Dra. Berta Roth

**Panelistas:**

Dr. Carlos Cardiello (RT), Dr. Pablo Castro Peña (RT),

Dra. María Luisa Filomia (RT), Dr. Carlos Pizzo (RT)

Dr. Eduardo Weltman (RT), H. Israelita Albert Einstein, San Pablo, Brasil

Dr. Enrique Díaz Cantón, Oncología, CEMIC, Buenos Aires

***18:15 – 18:35 hs. Entrega de Diplomas de Recertificación en Radioterapia***

---

**Apertura del Acto: Prof. Dr. Carlos Mercau, Presidente CRAMA**

***18:35 – 19:00 hs. Entrega de Diplomas “Miembro Honorario Extranjero”***

---